Delivery Order SPE2DB20D6037-SPE2DB25FTWE8

The Defense Logistics Agency awarded a delivery order valued at $6,708.87 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Ondansetron HCL 4 mg tablets (30-count units). The contract, awarded on August 19, 2025, with an ultimate completion date of August 20, 2025, operates under a firm fixed-price structure with no set-aside designation. The place of performance is listed as Conshohocken, Pennsylvania. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately $500 million through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide.

DMS Pharmaceutical Group, based in Park Ridge, Illinois, and registered in SAM.gov since 2001, has established itself as a critical supplier within the federal pharmaceutical supply chain. The company specializes in distributing branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to Department of Defense healthcare sites. As a woman-owned small business, DMS Pharmaceutical Group has consistently competed effectively for federal contracts with the DLA, leveraging its core business focus on providing medical supplies and medications to government healthcare systems. Ondansetron, an antiemetic medication commonly used to prevent nausea and vomiting, represents one of the routine pharmaceutical products the company supplies through its primary contract vehicle.